SCHEMBL2551037

SCHEMBL2551037

COCCn1c(-c2c[nH]c(-c3ccc4scnc4c3)n2)nc2ccc(Br)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 5/20 0.39
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CASR P41180 1/20 0.35
▸ BRD4 O60885 3/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ TRPV3 Q8NET8 1/20 0.33
▸ MAP3K11 Q16584 1/20 0.33
▸ NPM1 P06748 1/20 0.33
▸ ALK Q9UM73 1/20 0.33
▸ RIPK2 O43353 2/20 0.33
▸ PFKFB3 Q16875 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2552155 0.93 PTGER4 (0.47) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL2554816 0.91 KDM4E (0.37) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL2552122 0.90 PTGER4 (0.37) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL2551655 0.90 RIPK2 (0.37) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL2555588 0.89 HPGD (0.49) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL14576227 0.88 KDM4E (0.39) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL2550197 0.87 CASR (0.36) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL12284051 0.87 PTGER4 (0.41) PTGER4KDM4EHSD17B10RECQLHPGD
SCHEMBL12283704 0.87 PTGER4 (0.49) PTGER4NPC1POLBALOX15MAPK1
Hydrochloric Acid SCHEMBL2552919 0.87 PTGER4 (0.41) PTGER4KDM4EHSD17B10RECQLHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US claimed
EP-2552208-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 — — EP disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 PTGER4 3190/4885KDM4E 764/4885HSD17B10 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback